title: [Pristinamycin/Vitamin k antagonists drug interaction: a French pharmacovigilance database study].
abstract: OBJECTIVE
  To analyse pristinamycin/vitamin K antagonists (VKA) drug interaction by using data recorded in the French pharmacovigilance database (FPVB).
  
  
  METHODS
  All cases with an increase effect of a VKA and an association with pristinamycin recorded in the FPVB between 1985 and 2013 were included. Data concerning patients, VKA treatments and side effects were recorded for a descriptive analysis.
  
  
  RESULTS
  During this period, 31 reports with a VKA overdose after an association with pristinamycin were included. Fluindione is the most often involved VKA (77% of cases). In 20 cases (65.4%), VKA overdose caused bleeding and 24 cases (77.4%) were serious.
  
  
  CONCLUSIONS
  Although mechanism is unknown, pristinamycine/AVK drug interaction is a reality that needs to be reported in the summary of product characteristics of these drugs and better known by practitioners to act in patients' interest.
authors.affiliation: Centre régional de Pharmacovigilance de Bourgogne, Centre hospitalier universitaire de Dijon, Dijon, France.
authors.forename: Anne-Laure
authors.initials: AL
authors.lastname: Guiboux
authors.affiliation: Centre régional de Pharmacovigilance de Bourgogne, Centre hospitalier universitaire de Dijon, Dijon, France.
authors.forename: Anne
authors.initials: A
authors.lastname: Dautriche
authors.affiliation: Centre régional de Pharmacovigilance de Nice, Hôpital de Cimiez, Nice, France.
authors.forename: Fanny
authors.initials: F
authors.lastname: Rocher
authors.affiliation: Centre régional de Pharmacovigilance de Lyon, Hospices civils de Lyon, Lyon, France.
authors.forename: Mery
authors.initials: M
authors.lastname: Bruel
authors.affiliation: Centre régional de Pharmacovigilance de Bourgogne, Centre hospitalier universitaire de Dijon, Dijon, France.
authors.forename: Catherine
authors.initials: C
authors.lastname: Sgro
mesh_terms: D015110:4-Hydroxycoumarins / Q000008:administration & dosage / Q000009:adverse effects; D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems / Q000706:statistics & numerical data; D000368:Aged; D000369:Aged, 80 and over; D016208:Databases, Factual; D004347:Drug Interactions; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D007192:Indenes / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D060735:Pharmacovigilance; D025762:Pristinamycin / Q000008:administration & dosage / Q000009:adverse effects; D014812:Vitamin K / Q000008:administration & dosage / Q000009:adverse effects / Q000037:antagonists & inhibitors*
chemical_list: D015110:4-Hydroxycoumarins; D007192:Indenes; D025762:Pristinamycin; C011664:antivitamins K; D014812:Vitamin K